KYNTRA BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
KYNTRA BIO, INC. (KYNB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $15.14 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-16
- KYNTRA BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $15.14, a 770.11% increase from fiscal 2024.
- KYNTRA BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.74, a 76.07% decline from fiscal 2023.
- KYNTRA BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $7.27, a 50.61% decline from fiscal 2022.
- KYNTRA BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $14.72, a 58.63% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $15.14 10-K · filed 2026-03-16 |
| 2024-12-31 | $1.74 10-K · filed 2025-03-17 |
| 2023-12-31 | $7.27 10-K · filed 2024-02-26 |
| 2022-12-31 | $14.72 10-K · filed 2023-02-27 |
| 2021-12-31 | $35.58 10-K/A · filed 2022-03-04 |
| 2020-12-31 | $31.55 10-K · filed 2021-03-01 |
| 2019-12-31 | $53.75 10-K · filed 2020-03-02 |
| 2018-12-31 | $53.64 10-K · filed 2019-02-27 |
| 2017-12-31 | $26.95 10-K · filed 2018-02-27 |
| 2016-12-31 | $19.41 10-K · filed 2017-03-01 |
| 2015-12-31 | $27.27 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |